Thursday, January 21, 2021 7:56:46 AM
*INmune Bio shares are trading higher after the company announced results for its Phase 1B study of XPro1595. The results show a decrease in biomarkers of neuroinflammation across multiple measures and assays, including cerebrospinal fluid and MRI.
$PDSB CD8+ (killer) T-cells. T cell platform is next.
$INMB
Recent INMB News
- INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/25/2024 01:00:00 PM
- INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update • GlobeNewswire Inc. • 03/28/2024 08:01:53 PM
- INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 • GlobeNewswire Inc. • 03/26/2024 08:01:00 PM
- INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy • GlobeNewswire Inc. • 03/13/2024 12:00:00 PM
- INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™ • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/12/2024 02:00:00 PM
- INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024 • GlobeNewswire Inc. • 02/06/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:02:36 PM
- INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology • GlobeNewswire Inc. • 01/16/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:00:28 PM
- INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:15:31 PM
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 12/18/2023 09:05:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:01:18 PM
- INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA • GlobeNewswire Inc. • 12/18/2023 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:00:09 PM
- INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 11/29/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 09:00:36 PM
- INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease • GlobeNewswire Inc. • 11/27/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM